肿瘤异质性相关调控基因对食管鳞癌患者化疗敏感性的预测价值  

Expression of tumor heterogeneity-related genes in esophageal squamous cell carcinoma and its predictive value for chemotherapy sensitivity

作　　者：王文辉[1] 齐元玲[1] 任海朋[1] 徐谦[1] 

机构地区：[1]山东省潍坊市人民医院肿瘤内科,261042

出　　处：《中华老年医学杂志》2015年第6期635-637,共3页Chinese Journal of Geriatrics

基　　金：山东潍坊市科学技术局支持项目（2012-1276）

摘　　要：目的 探讨切除修复交叉互补修复基因1（ERCC1）和核糖核苷酸还原酶基因1（RRM1）在食管鳞癌患者中的表达,以及ERCC1和RRM1的mRNA表达对食管鳞癌术后复发患者化疗敏感性的关系. 方法 选择2008年1月至2011年12月医院收治的77例食管鳞癌术后复发患者为研究对象,应用实时荧光定量反转录聚合酶链反应（RT-PCR）检测癌变组织中ERCC1和RRM1的表达,分析ERCC1和RRM1 mRNA水平与患者的近期化疗疗效的相关性. 结果 ERCC1和RRM1 mRNA相对表达水平Ⅰa期、Ⅰb期、Ⅱa期、Ⅱb期分别为：ERCC1 （0.578±0.081,0.560±0.084,0.521±0.080,0.464±0.091）,RRM1 （0.511±0.089,0.539±0.086,0.584±0.092,0.637±0.101）;患者分期越高,其ERCC1 mRNA水平越低（t=2.679,P=0.034）,RRM1 mRNA水平越高（t=2.952,P=0.025）.两个基因不同临床疗效（完全缓解、部分缓解、稳定、进展）的表达为ERCC1 （0.487±0.097,0.511±0.095,0.552±0.086,0.568±0.088）,RRM1 （0.504±0.091,0.544±0.095,0.595±0.093,0.616±0.097）;ERCC1和RRM1 mRNA表达水平与临床化疗效果呈负相关（r=0.567,P=0.032）. 结论 ERCC1和RRM1 mRNA的表达水平与食管鳞癌的术后分期和临床化疗敏感性具有一定相关,可作为预测食管鳞癌患者临床化疗敏感性的指标.Objective To investigate the expression of excision repair cross-complementation group 1 （ERCC1） and ribonucleotide reductase subunit M1 （RRM1） in patients with esophageal squamous cell carcinoma,and the relationship between the expression of ERCC1 and RRM1 genes and chemotherapy sensitivity.Methods A total of 77 patients with esophageal squamous cell carcinoma admitted in hospital from Jan.2008 to Dec.2012 were recruited.ERCC1 and RRM1 mRNA levels in the cancerous tissue were detected by real-time fluorescent quantitative RT PCR.The relationship between short-term effects of chemotherapy and ERCC1 and RRM1 mRNA levels was analyzed.Results Levels of mRNA in stages Ⅰ a,Ⅰ b,Ⅱ a,and Ⅱ b were （0.578±0.081）,（0.560±0.084）,（0.521±0.080）,（0.464±0.091） for ERCC1 and（0.511±0.089）,（0.539± 0.086）,（0.584±0.092）,（0.637±0.101）for RRM1,respectively.As the clinical stage advanced,the ERCC1 mRNA level declined and the RRM1 mRNA level increased （t=2.679 and 2.952,P =0.034 and 0.025,respectively）.Levels of mRNA in patients with complete remission,partial remission,stable disease and progressive disease were （0.487 ± 0.097,0.511 ± 0.095,0.552 ± 0.086,0.568 ± 0.088） for ERCC1 and（0.504±0.091,0.544±0.095,0.595±0.093,0.616±0.097） for RRM1,respectively.The clinical effect of chemotherapy was negatively correlated with mRNA expression of ERCC1 and RRM1 （r=0.567,P=0.032）.Conclusions Levels of ERCC1 and RRM1 mRNA expression are correlated with the staging of esophageal squamous cell carcinoma and chemotherapy sensitivity,and can be used as a predictive parameter for chemotherapy sensitivity in patients with esophageal squamous cell carcinoma.

关 键 词：DNA修复 食管肿瘤 抗肿瘤联合化疗方案 基因 肿瘤抑制 

分 类 号：R735.1[医药卫生—肿瘤]